Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sanofi : Short-term turn-around to the downside ahead

share with twitter share with LinkedIn share with facebook
share via e-mail
09/10/2019 | 03:17am EDT
short sell
Live
Entry price : 77.8€ | Target : 72.3€ | Stop-loss : 81.6€ | Potential : 7.07%
The recently observed upswing has shown some signs of exhaustion, which makes for good timing to employ a short strategy with a short term perspective.
Investors should open a short trade and target the € 72.3.
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Summary
  • For a short-term investment strategy, the company has poor fundamentals.

Strengths
  • The company returns high margins, thereby supporting business profitability.
  • Over the last seven days, analysts have been revising upwards their EPS estimates for the company.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The stock is in a well-established, long-term rising trend above the technical support level at 75.95 EUR

Weaknesses
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • With a 2019 P/E ratio at 25.45 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart
Subsector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
SANOFI5.12%110 279
JOHNSON & JOHNSON1.07%345 150
ROCHE HOLDING LTD.10.52%236 116
MERCK AND COMPANY8.11%211 513
PFIZER-15.44%204 151
NOVARTIS18.45%200 777
NOVO NORDISK AS14.89%118 168
AMGEN0.41%117 224
ASTRAZENECA16.89%112 136
ABBVIE-23.52%104 248
ELI LILLY AND COMPANY-4.17%101 512
Autres valeurs du secteur

Jordan Dufee
© Zonebourse.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (EUR)
Sales 2019 36 254 M
EBIT 2019 9 474 M
Net income 2019 4 196 M
Debt 2019 14 641 M
Yield 2019 3,96%
P/E ratio 2019 25,5x
P/E ratio 2020 16,8x
EV / Sales2019 3,15x
EV / Sales2020 2,97x
Capitalization 99 582 M
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Average target price 88,57  €
Last Close Price 79,53  €
Spread / Highest target 25,7%
Spread / Average Target 11,4%
Spread / Lowest Target -0,67%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development